David M. Mauney
co-founder and Managing Director @ DeNovo Ventures
Charlotte, United States
David M. Mauney is a Series B investor at DeNovo Ventures in Charlotte focused on Health Care and Medical. David M. Mauney is the Managing Director and one of the co-founders of De Novo Ventures, a distinguished healthcare investment firm. Prior to co-founding De Novo, David was a Partner at Asset Management Company (AMC), where he worked with Pitch Johnson as the lead partner in healthcare investments. At AMC, he led seed and early stageinvestments in TriVascular (acquired by Boston Scientific), Novare Surgical Systems (licensed to Johnson & Johnson), Enteric Medical Technologies (acquired by Boston Scientific), and participated in seven financings of technology companies.David was the first employee and Director of Business Development for Fox Hollow Technologies (Nasdaq: EVVV) and worked in product management for Heartport (acquired by Johnson & Johnson). David sits on the boards of Articulinx, ProMed, Simpirica, Tria Beauty, and Ventus Medical. He also represented De Novo on investments in CyroVascular and Lumend.David earned an M.D. from Dartmouth Medical School and a B.A. from Duke University.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries David M. Mauney invests in
Stages David M. Mauney invests in
Countries David M. Mauney invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (40%)
- Medical 3 (30%)
- Biotechnology 3 (30%)
- Therapeutics 2 (20%)
- Beauty 1 (10%)
Stage
- Series B 2 (20%)
- Series C 2 (20%)
- Series D 2 (20%)
- Series A 1 (10%)
- Funding Round 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Sidecar Health is an insurtech company that provides a personalized health insurance platform. Its platform offers customizable plans based on coverage needs and budget while being completely transparent about medical costs and payouts with comparable coverage and permits fast and easy transactions through a credit card to charge medical expensesupfront at the doctor's office and pharmacy of their choice, enabling consumers to get suitable and affordable health insurance plans.The company was founded in 2018 and is headquartered in El Segundo, California . | $165M / Series D / Jun 26, 2024 | ||
| Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $255M / Series C / Aug 23, 2023 | ||
| Bitterroot Bio leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease. | $145M / Series A / Jun 07, 2023 | ||
| Oshi Health is a virtual-first gastroenterology (GI) clinic that diagnoses, treats and remotely monitors digestive (GI) conditions. Patients work with Oshi Health's integrated care team of gastroenterologists and GI-specialized nurse practitioners, registered dietitians, behavioral psychologists and health coaches to determine the root causesof their symptoms and use a personalized care plan that includes medication, dietary interventions and stress/anxiety reduction to get symptoms under control. This yields improved health outcomes, quality of life, satisfaction with care and workplace productivity while reducing overall healthcare cost. | $30M / Series B / Apr 10, 2023 | ||
| Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications. | $73M / Series B / Mar 17, 2022 | ||
| TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah,Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California. | $45.5M / Private Equity / Jul 09, 2013 | ||
| TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah,Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California. | $7.5M / Oct 02, 2012 | ||
| Simpirica Spine was founded in 2006 to develop minimally invasive, flexion-restricting stabilization devices. | $22M / Series C / Sep 20, 2011 | ||
| TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah,Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California. | $26.3M / Feb 10, 2011 | ||
| TRIA Beauty, Inc. develops and markets light-based therapeutic beauty systems for the consumer market. The company provides a diode laser hair removal system for home use. It offers its products through a network of retailers in California, Florida, Illinois, Louisiana, Minnesota, Nevada, New Jersey, New York, Pennsylvania, Tennessee, Texas, Utah,Virginia, and Washington. TRIA Beauty, Inc. was formerly known as SpectraGenics, Inc. and changed its name to TRIA Beauty, Inc. in July 2008. The company was founded in 2003 and is based in Pleasanton, California. | $20M / Series D / May 24, 2007 |
Co-Investors
About DeNovo Ventures
DeNovo Ventures was formed in 2000 by seasoned investors and experienced medical device entrepreneurs who sought to share the lessons learned from a history of successful investing and building successful companies. They believed that their unique combination of skills and perspectives could help entrepreneurs to build companies which would havesignificant clinical impact and generate superior returns. Seven years later, this belief continues to hold true, demonstrated by investment success in selected medical device and biotechnology companies. With $650 million under management, De Novo has made more than 40 investments in medical devices and biotechnology across three funds. They invest in all stages of enterprise development and growth – from early stage to late stage. The unique background of leading companies as entrepreneurs and operating executives from start to exit enables us to advise entrepreneurs and management teams over the full life cycle of the company.
DeNovo Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Joe Mandato
Managing Director
|
|||
|
David M. Mauney
co-founder and Managing Director
|
|||
Frederick Dotzler
Managing Director
|
|||
Jay Watkins
Managing Director
|
|||
Richard Ferrari
Co - Founder & Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David M. Mauney invest in?
David M. Mauney invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Series C stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact David M. Mauney?
Public channels for David M. Mauney include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did David M. Mauney last invest?
The most recent investment recorded for David M. Mauney closed in Jun 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
